Clover Health Investments, Corp.
NASDAQ:CLOVMedical - Healthcare Plans
+$0.17 today
- Market cap
- $2.21B
- Beta
- 2.48
- P/E (TTM)
- -45.6
- EPS (TTM)
- -$0.11
Volume 8.05M
Average 7.31M
CLOV Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Clover Health Investments, Corp.NASDAQ: CLOV
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures grows, but more slowly than its trailing trend
Q2 FY2026 capital expenditures of $682K (cash outflow) rose 19.9% year over year, behind the +92.4% change in trailing-twelve-month capital expenditures. Sequentially, it fell 20.1% from the prior quarter. Over 3 fiscal years it compounded at -23.0% a year.
Context
- Capital expenditures amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +19.9% toward the trailing-twelve-month pace of +92.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (2.04M) USD
- Year-over-year change
- -31.3%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.04M) | -31.3% |
| FY2024 | 2024-12-31 | (1.56M) | -166.4% |
| FY2023 | 2023-12-31 | (584K) | +86.9% |
| FY2022 | 2022-12-31 | (4.47M) | -517.8% |
| FY2021 | 2021-12-31 | (723K) | — |
Capital Expenditures vs competitors
How CLOV compares with its peers on the latest reported figures
- CLOV's LTM Jun 2026 capital expenditures of $2.83M is the smallest of the 7 companies compared; the peer median is $695M.
- Its year-over-year change of +92.4% is the highest of 7, against a peer median of +13.3%.
- Capital expenditures amounts to 0.1% of revenue for CLOV, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.02B | +8.4% | +1.3% | 0.7% | |
| LTM Sep 2026 | $1.16B | -5.1% | -2.2% | 0.4% | |
| LTM Jun 2026 | $798M | +22.8% | -8.6% | 0.4% | |
| LTM Sep 2026 | $592M | +18.9% | -21.7% | 0.4% | |
| LTM Jun 2026 | $38.63M | +18.2% | +7.8% | 0.3% | |
| LTM Mar 2026 | $15.37M | -60.1% | +4.0% | 0.4% | |
| LTM Jun 2026 | $2.83M | +92.4% | -23.0% | 0.1% | |
| Peer median (excluding CLOV) | $695M | +13.3% | -0.5% | 0.4% | |
Competitors are the stored peer set for CLOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (587.76M) | (339.57M) | (213.36M) | (43.01M) | (85.55M) |
| Depreciation & Amortization | 1.25M | 1.19M | 2.51M | 1.33M | 1.69M |
| Deferred Income Tax | (66.09M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 163.72M | 164.31M | 140.93M | 114.33M | 103.66M |
| Change in Working Capital | 192.67M | (2.36M) | (55.43M) | 12.86M | (84.2M) |
| Accounts Receivables | (9.39M) | (8.03M) | 0 | (6.55M) | (65.95M) |
| Inventory | 9.39M | 0 | 0 | 0 | 0 |
| Accounts Payables | 5.31M | 7.64M | 4.74M | (2.62M) | 1.65M |
| Other Working Capital | 187.37M | (1.97M) | (60.17M) | 22.03M | (19.9M) |
| Other Non-Cash Items | 13.88M | (27.49M) | 9.48M | (50.66M) | (2.53M) |
| Operating Cash Flow | (282.33M) | (203.93M) | (115.87M) | 34.85M | (66.93M) |
| Capital Expenditures | (723K) | (4.47M) | (584K) | (1.56M) | (2.04M) |
| Acquisitions (Net) | 434.72M | (16.2M) | 0 | 0 | 0 |
| Purchases of Investments | (876.25M) | (369.65M) | (175.57M) | (201.24M) | (205.1M) |
| Sales of Investments | 441.53M | 485.45M | 316.16M | 203.36M | 211.22M |
| Other Investing Activities | (434.72M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (435.45M) | 95.13M | 140.01M | 565K | 4.08M |
| Debt Repayment | (30.93M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 289.92M | 1.4M | 1.15M | 902K | 1.81M |
| Common Stock Repurchased | (147K) | (6.36M) | (6.22M) | (18.26M) | (55.2M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 666.55M | 0 | (28.79M) | 0 | 0 |
| Financing Cash Flow | 925.39M | (4.96M) | (33.86M) | (17.36M) | (53.38M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 207.62M | (113.76M) | (9.72M) | 18.05M | (116.24M) |
| Free Cash Flow | (283.05M) | (208.39M) | (116.46M) | 33.29M | (68.98M) |
Clover Health Investments, Corp.
NASDAQ:CLOV
Intrinsic Alpha fair value
Locked
Current Price
$4.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.